Search results for "PORIN"

showing 10 items of 260 documents

Entropy–enthalpy compensation at the single protein level: pH sensing in the bacterial channel OmpF

2014

The pH sensing mechanism of the OmpF channel operates via ligand modification: increasing acidity induces the replacement of cations with protons in critical binding sites decreasing the channel conductance. Aside from the change in enthalpy associated with the binding, there is also a change in the microscopic arrangements of ligands, receptors and the surrounding solvent. We show that the pH-modulation of the single channel conduction involves small free energy changes because large enthalpic and entropic contributions change in opposite ways, demonstrating an approximate enthalpy–entropy compensation for different salts and concentrations. We wish to acknowledge the support from the Span…

Models Molecularentropy-enthalpy compensationChemistryLigandEntropyEnthalpyBinding energyElectric ConductivitypH sensingPorinsConductanceThermodynamicsHydrogen-Ion ConcentrationThermal conductionbinding energyPotassium ChlorideSolventModels ChemicalComputer SimulationGeneral Materials Sciencesense organsBinding siteskin and connective tissue diseasesentropyEntropy (order and disorder)
researchProduct

Redistribution of aquaporin-4 in human glioblastoma correlates with loss of agrin immunoreactivity from brain capillary basal laminae

2003

Vasogenic edema is one of the most serious clinical problems in brain tumors and tightly connected to water shifts between the different fluid compartments in the brain. Aquaporin water channels have been recognized to have an important impact on the development of edematous swelling in the brain. Astrocytes, which are believed to induce or at least maintain the blood-brain barrier in the brain capillary endothelial cells, express the aquaporin isoform AQP4. Normally, AQP4 is highly concentrated in the glial membrane where astrocytes contact mesenchymal space, such as perivascular or brain superficial regions. Parenchymal membranes do not show any immunocytochemical AQP4-specific signal. We…

Models NeurologicalSynucleinsAquaporinNerve Tissue ProteinsBiologyAquaporinsBlood–brain barrierBasement MembranePathology and Forensic MedicineCellular and Molecular NeuroscienceGliomaUtrophinmedicineExtracellularAnimalsHumansAgrinDystroglycansAquaporin 4Membrane GlycoproteinsAgrinBrain NeoplasmsEndothelial Cellsmedicine.diseaseImmunohistochemistryRatsCell biologyCytoskeletal Proteinsmedicine.anatomical_structureAquaporin 4Immunologysense organsNeurology (clinical)GlioblastomaAstrocyteActa Neuropathologica
researchProduct

Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study

2020

Background: Cyclosporine A (CsA) is one of the systemic therapeutic options for moderate-to-severe psoriasis, based on its efficacy and rapidity of action. The current study investigated the response to CsA in patients with moderate-to-severe plaque psoriasis. Materials and Methods: TRANSITION was an observational, cross-sectional, multicentre study which evaluated the proportion of partial- and suboptimal-responders among patients with moderate-to-severe plaque psoriasis treated with continuous CsA for >= 12 weeks. Patients demonstrating a Psoriasis Area and Severity Index (PASI) response of >= 90, >= 75 and <90, >= 50 and <75 and <50 were defined as responders, subopt…

Moderate to severeMalemedicine.medical_specialtysystemic therapy.macromolecular substancesDermatologySystemic therapySeverity of Illness Indexsystemic therapy030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePsoriasisMedicineHumansPsoriasisIn patientPASI; cyclosporine A; moderate to severe plaque psoriasis; systemic therapy030203 arthritis & rheumatologyPlaque psoriasisbusiness.industryPASIMiddle Agedmedicine.diseasemoderate to severe plaque psoriasiDermatologycyclosporine A; moderate to severe plaque psoriasis; PASI; systemic therapyCross-Sectional StudiesTreatment OutcomeCyclosporineQuality of LifeFemalebusinesscyclosporine Amoderate to severe plaque psoriasis
researchProduct

Simple molecular model for the binding of antibiotic molecules to bacterial ion channels

2003

A molecular model aimed at explaining recent experimental data by Nestorovich et al. [Proc. Natl. Acad. Sci. USA 99, 9789 (2002)] on the interaction of ampicillin molecules with the constriction zone in a channel of the general bacterial porin, OmpF (outer membrane protein F), is presented. The model extends T. L. Hill’s theory for intermolecular interactions in a pair of binding sites [J. Am. Chem. Soc. 78, 3330 (1956)] by incorporating two binding ions and two pairs of interacting sites. The results provide new physical insights on the role of the complementary pattern of the charge distributions in the ampicillin molecule and the narrowest part of the channel pore. Charge matching of int…

Molecular modelChemistrypHMolecular biophysicsIntermolecular forceMicroorganisms:QUÍMICA::Química física [UNESCO]General Physics and AstronomyBiochemistryIonCrystallographyBonds (Chemical)Computational chemistryPorinMicroorganisms ; Bonds (Chemical) ; Intermolecular Mechanics ; Biochemistry ; Molecular Biophysics ; pHUNESCO::QUÍMICA::Química físicaMoleculeIntermolecular MechanicsPhysical and Theoretical ChemistryBinding siteIon channelMolecular Biophysics
researchProduct

Tetraspan vesicle membrane proteins: Synthesis, subcellular localization, and functional properties

2002

Tetraspan vesicle membrane proteins (TVPs) are characterized by four transmembrane regions and cytoplasmically located end domains. They are ubiquitous and abundant components of vesicles in most, if not all, cells of multicellular organisms. TVP-containing vesicles shuttle between various membranous compartments and are localized in biosynthetic and endocytotic pathways. Based on gene organization and amino acid sequence similarities TVPs can be grouped into three distinct families that are referred to as physins, gyrins, and secretory carrier-associated membrane proteins (SCAMPs). In mammals synaptophysin, synaptoporin, pantophysin, and mitsugumin29 constitute the physins, synaptogyrin 1-…

Multicellular organismBiochemistryMembrane proteinVesicleSynaptoporinBiologySubcellular localizationPeptide sequenceTransmembrane proteinExocytosisCell biology
researchProduct

Signal transduction pathways of membrane expression of proteinase 3 (PR‐3) in human endothelial cells

1997

At present, the exact mechanism of the pathogenic effect of anti-PR-3 antibodies remains unknown. Interaction of anti-neutrophil cytoplasmic antibodies (ANCAs) with human umbilical vein endothelial cells (HUVECs) may play a key role. Recently we were able to show that ANCAs recognize their target antigen, PR-3, translocated into the membrane of HUVECs. The objective of this study was to investigate regulation, i.e. signal transduction pathways, of PR-3 expression in endothelial cells. HUVECs were isolated according to the method of Jaffe et al. and cultured under standard conditions. A cyto-enzyme-linked immunosorbent assay (ELISA) with unfixed cells was performed. Membrane-expressed PR-3 w…

MyeloblastinClinical BiochemistryBiologyBiochemistrychemistry.chemical_compoundmedicineHumansStaurosporineProtein Kinase CProtein kinase CTumor Necrosis Factor-alphaCell MembraneSerine EndopeptidasesGeneral MedicineKT5720Cell biologyEndothelial stem cellCalphostin CchemistryBiochemistrySecond messenger systemDactinomycinPhorbolTetradecanoylphorbol AcetateEndothelium VascularSignal transductionSignal Transductionmedicine.drugEuropean Journal of Clinical Investigation
researchProduct

Randomized Comparative Trial with Ceftizoxime and Cefotaxime in Urinary Tract Infections

1984

Ceftizoxime, a new, semisynthetic, beta-lactamase-resistant cephalosporin, is not metabolized in man and is excreted almost entirely as the original active compound in the urine. The efficacy and safety of ceftizoxime were assessed in 80 patients with acute and chronic urinary infections, with and without associated pathological conditions, in comparison with cefotaxime. Two dosage schedules, 1 g or 0.5 g every 12 h, i.v. or i.m. for 10 days, were adopted according to the severity of each case and to separate randomization tables for each schedule; causal agents were all sensitive to both drugs in vitro. The overall results were excellent. Safety was excellent in almost all cases. In this t…

NephrologyAdultMalemedicine.medical_specialtyCefotaximeRandomizationAdolescentmedicine.drug_classUrologyUrinary systemCephalosporin030232 urology & nephrologyCefotaximeUrineRandom Allocation03 medical and health sciences0302 clinical medicineInternal medicineCeftizoximemedicineHumansAgedClinical Trials as Topicbusiness.industryCeftizoximeDosing regimenBacterial InfectionsDrug ToleranceGeneral MedicineMiddle AgedComparative trialSurgeryNephrology030220 oncology & carcinogenesisUrinary Tract InfectionsFemaleSafetybusinessmedicine.drugUrologia Journal
researchProduct

Risk factors and interventional strategies for BK polyomavirus infection after renal transplantation.

2012

BK virus (BKV)-induced viraemia after renal transplantation can be associated with severe impairment of graft function. This study evaluated possible risk factors for BKV replication and examined the outcomes following various currently used treatment approaches.Fifty-seven renal transplant recipients with BKV viraemia were retrospectively compared with 71 BKV-negative recipients to identify risk factors for BKV viraemia. Furthermore, outcome and graft function in 14 patients with BKV replication, in whom mycophenolate mofetil (MMF) was discontinued with a dose reduction of the remaining immunosuppressants, were compared with 32 patients in whom both MMF and the additional immunosuppressant…

NephrologyAdultMalemedicine.medical_specialtyvirusesUrologyLymphocytemedicine.medical_treatmentPrednisoloneAnti-Inflammatory AgentsKaplan-Meier Estimatemedicine.disease_causeVirus ReplicationGastroenterologyTacrolimusRisk FactorsInternal medicineConfidence IntervalsOdds RatioMedicineHumansLymphocyte CountWarm IschemiaRetrospective StudiesPolyomavirus Infectionsbusiness.industryGraft Survivalvirus diseasesImmunosuppressionOdds ratioMiddle AgedMycophenolic AcidViral LoadKidney TransplantationTacrolimusBK virusTransplantationTumor Virus Infectionsmedicine.anatomical_structureNephrologyBK VirusImmunologyCyclosporineDrug Therapy CombinationFemalebusinessViral loadImmunosuppressive AgentsScandinavian journal of urology and nephrology
researchProduct

Involvement of PKC and NF-κB in Nitric Oxide Induced Apoptosis in Human Coronary Artery Smooth Muscle Cells

2001

Apoptosis of vascular smooth muscle cells is critically involved in progression of atherosclerosis and may prevent intimal hyperplasia in restenosis and vascular remodeling. Nitric oxide (NO) is known to induce apoptosis, but the signaling pathways still remain unclear. We investigated p53 accumulation, protein kinase C (PKC) activation and nuclear transcription factor (NF-kappaB) binding activity as possible signaling mechanisms of NO-induced apoptosis. Apoptosis was induced dose-dependently with the NO-donors sodiumnitroprusside (SNP: 232+/-48%) and SIN-1 (241+/-90% of actinomycin D induced apoptosis; means +/- SEM, *por =0.05 vs. control) in HSMC. Inhibition of PKC significantly attenuat…

Nitroprussidemedicine.medical_specialtyVascular smooth muscleIntimal hyperplasiaPhysiologyApoptosisDNA FragmentationNaphthalenesNitric OxideMuscle Smooth VascularNitric oxidechemistry.chemical_compoundNF-KappaB Inhibitor alphaRestenosisInternal medicinemedicineHumansNitric Oxide DonorsEnzyme InhibitorsCells CulturedProtein Kinase CProtein kinase CCell Nucleusbusiness.industryNF-kappa BNF-κBStaurosporinemedicine.diseaseCoronary VesselsDNA-Binding Proteinsmedicine.anatomical_structurechemistryApoptosisMolsidomineCancer researchCardiologyI-kappa B ProteinsTumor Suppressor Protein p53businessArteryCellular Physiology and Biochemistry
researchProduct

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing live…

2010

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibito…

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinIntracellular Signaling Peptides and Proteins - antagonists & inhibitors metabolismKaplan-Meier Estimate312 Clinical medicineProtein-Serine-Threonine KinaseLiver transplantationTHERAPYStudy ProtocolImmunosuppressive Agentendothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model0302 clinical medicineRENAL-CELL CARCINOMARisk FactorsRecurrenceSurgical oncologyMedicine and Health SciencesLiver Neoplasms - drug therapy enzymology mortality surgerySirolimuProspective StudiesTUMOR PROGRESSIONTransplantation Homologoueducation.field_of_studyliver transplantationTOR Serine-Threonine KinasesLiver NeoplasmsIntracellular Signaling Peptides and ProteinsImmunosuppressionhepatocellular carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCANCER3. Good healthEuropeMulticenter StudyTreatment OutcomeTARGETsirolimusOncologyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaRandomized Controlled TrialmTORCarcinoma Hepatocellular - drug therapy enzymology mortality surgery030211 gastroenterology & hepatologyImmunosuppressive AgentsRCTHumanmedicine.drugCanadamedicine.medical_specialtyCarcinoma HepatocellularTime FactoreducationPopulationLiver Transplantation - adverse effects mortalityProtein Serine-Threonine Kinaseslcsh:RC254-282Disease-Free Survival03 medical and health sciencesInternal medicineGeneticsmedicineTransplantation HomologousHumansComparative StudyRapamycinddc:610educationProtein-Serine-Threonine Kinases - antagonists & inhibitors metabolismKaplan-Meiers Estimatebusiness.industryRisk FactorAustraliaImmunosuppressive Agents - therapeutic useSirolimus - therapeutic useEFFICACYHumans; Liver Transplantation; Hepatocellular Carcinoma; Randomized Controlled Trial; RCT; Multicenter Study; Comparative Study; Rapamycin; mTOR; Sirolimusmedicine.diseaseSurgeryMODELTransplantationClinical trialProspective StudieIntracellular Signaling Peptides and ProteinSirolimusENDOTHELIAL GROWTH-FACTORCYCLOSPORINERAPAMYCINbusiness
researchProduct